Eyes on New Product Development: Long-Acting Ocular Drug Delivery Technologies Addressing Unmet Needs in Ophthalmology

Novack G.D. Ophthalmic drug delivery: Development and Regulatory Considerations. Clin. Pharmacol. Ther. 85:539–543, 2009.

Anonymous. 20-5026- Genus Medical Technologies LLC v. FDA, 2021.

Anonymous. Genus Medical Technologies LLC versus Food and Drug Administration; Request for Information and Comments. Fed. Reg. 86:43553–43555, 2021.

Anonymous. Certain ophthalmic products: policy regarding compliance with 21 CFR Part 4; guidance for industry. Fed. Reg. 87:16391–16393, 2022.

Baker N.D. , Barnebey H.S. , Moster M.R. , et al. Ab-externo microshunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology. 128:1710–1721, 2021.

Gallardo M.J. , Pyfer M.F. , Vold S.D. , et al. Canaloplasty and trabeculotomy combined with phacoemulsification for glaucoma: 12-month results of the GEMINI study. Clin. Ophthalmol. 16:1225–1234, 2022.

Chawla D.S. How a site peddles author slots in reputable publishers' journals. Science. 376:231–232, 2022.

Maron J.L. Pledging to address scientific bias in published literature. Clin. Ther. 44:349–350, 2022.

Morrow R.L. , Mintzes B. , Gray G. , Law M.R. , Garrison S. , and Dormuth C.R. Industry sponsor influence in clinical trial reporting in Canada: a qualitative interview study. Clin. Ther. 44:374–388, 2022.

Zarin D.A. , and Selker H.P. Reporting of clinical trial results: aligning incentives and requirements to do the right thing. Clin. Ther. 44:439–441, 2022.

Anonymous. Withdrawing rule on securing updated and necessary statutory evaluations timely. Fed. Reg. 87:32246–32288, 2022.

Loftus P. FDA rejects two proposed cancer drugs developed in China. Wall. St. J. 2022. Accessed May 2, 2022.